Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Retention of Alzheimer Disease Research Participants.

Grill JD, Kwon J, Teylan MA, Pierce A, Vidoni ED, Burns JM, Lindauer A, Quinn J, Kaye J, Gillen DL, Nan B.

Alzheimer Dis Assoc Disord. 2019 Sep 26. doi: 10.1097/WAD.0000000000000353. [Epub ahead of print]

PMID:
31567302
2.

Public Understanding and Opinions regarding Genetic Research on Alzheimer's Disease.

Kent S, Bardach SH, Zhang X, Abner EL, Grill JD, Jicha GA.

Public Health Genomics. 2018;21(5-6):228-237. doi: 10.1159/000501464. Epub 2019 Jul 19.

PMID:
31326966
3.

Response to "Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure".

Grill JD, Cox CG, Harkins K, Karlawish J.

Alzheimers Res Ther. 2019 Jun 4;11(1):51. doi: 10.1186/s13195-019-0504-1. No abstract available.

4.

Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?

Grill JD, Nuño MM, Gillen DL; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2019 Apr-Jun;33(2):104-112. doi: 10.1097/WAD.0000000000000303.

PMID:
30958413
5.

Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial.

Grill JD, Cox CG, Harkins K, Karlawish J.

Alzheimers Res Ther. 2018 Dec 22;10(1):125. doi: 10.1186/s13195-018-0452-1.

6.

A Preliminary Study of Clinical Trial Enrollment Decisions Among People With Mild Cognitive Impairment and Their Study Partners.

Cox CG, Ryan B A MM, Gillen DL, Grill JD.

Am J Geriatr Psychiatry. 2019 Mar;27(3):322-332. doi: 10.1016/j.jagp.2018.10.016. Epub 2018 Nov 3.

PMID:
30522811
7.

Study partners: essential collaborators in discovering treatments for Alzheimer's disease.

Largent EA, Karlawish J, Grill JD.

Alzheimers Res Ther. 2018 Sep 27;10(1):101. doi: 10.1186/s13195-018-0425-4.

8.

Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study.

Torosyan N, Sethanandha C, Grill JD, Dilley ML, Lee J, Cummings JL, Ossinalde C, Silverman DH.

Exp Gerontol. 2018 Oct 1;111:118-121. doi: 10.1016/j.exger.2018.07.009. Epub 2018 Jul 10.

PMID:
30006299
9.

Recruiting the Oldest-old for Clinical Research.

Melikyan ZA, Greenia DE, Corrada MM, Hester MM, Kawas CH, Grill JD.

Alzheimer Dis Assoc Disord. 2019 Apr-Jun;33(2):160-162. doi: 10.1097/WAD.0000000000000260. No abstract available.

PMID:
29734262
10.

Constructing a Local Potential Participant Registry to Improve Alzheimer's Disease Clinical Research Recruitment.

Grill JD, Hoang D, Gillen DL, Cox CG, Gombosev A, Klein K, O'Leary S, Witbracht M, Pierce A.

J Alzheimers Dis. 2018;63(3):1055-1063. doi: 10.3233/JAD-180069.

PMID:
29710723
11.

Participant Satisfaction With Learning Alzheimer Disease Clinical Trial Results.

Pierce AL, Cox CG, Nguyen HT, Hoang D, Witbracht M, Gillen DL, Grill JD.

Alzheimer Dis Assoc Disord. 2018 Oct-Dec;32(4):366-368. doi: 10.1097/WAD.0000000000000258. No abstract available.

12.

Study partners should be required in preclinical Alzheimer's disease trials.

Grill JD, Karlawish J.

Alzheimers Res Ther. 2017 Dec 6;9(1):93. doi: 10.1186/s13195-017-0327-x. Review.

13.

African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials.

Zhou Y, Elashoff D, Kremen S, Teng E, Karlawish J, Grill JD.

Alzheimers Dement (N Y). 2016 Oct 15;3(1):57-64. doi: 10.1016/j.trci.2016.09.004. eCollection 2017 Jan.

14.

Attitudes toward clinical trials across the Alzheimer's disease spectrum.

Nuño MM, Gillen DL, Dosanjh KK, Brook J, Elashoff D, Ringman JM, Grill JD.

Alzheimers Res Ther. 2017 Oct 4;9(1):81. doi: 10.1186/s13195-017-0311-5.

15.

Communicating mild cognitive impairment diagnoses with and without amyloid imaging.

Grill JD, Apostolova LG, Bullain S, Burns JM, Cox CG, Dick M, Hartley D, Kawas C, Kremen S, Lingler J, Lopez OL, Mapstone M, Pierce A, Rabinovici G, Roberts JS, Sajjadi SA, Teng E, Karlawish J.

Alzheimers Res Ther. 2017 May 4;9(1):35. doi: 10.1186/s13195-017-0261-y. Review.

16.

Recruiting to preclinical Alzheimer's disease clinical trials through registries.

Grill JD.

Alzheimers Dement (N Y). 2017 Jun;3(2):205-212. doi: 10.1016/j.trci.2017.02.004.

17.

Patient and caregiver reactions to clinical amyloid imaging.

Grill JD, Cox CG, Kremen S, Mendez MF, Teng E, Shapira J, Ringman JM, Apostolova LG.

Alzheimers Dement. 2017 Aug;13(8):924-932. doi: 10.1016/j.jalz.2017.01.001. Epub 2017 Feb 4.

18.

Attitudes toward Potential Participant Registries.

Grill JD, Holbrook A, Pierce A, Hoang D, Gillen DL.

J Alzheimers Dis. 2017;56(3):939-946. doi: 10.3233/JAD-160873.

19.

Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care.

Apostolova LG, Haider JM, Goukasian N, Rabinovici GD, Chételat G, Ringman JM, Kremen S, Grill JD, Restrepo L, Mendez MF, Silverman DH.

Alzheimers Dement (Amst). 2016 Dec 18;5:15-22. doi: 10.1016/j.dadm.2016.12.001. eCollection 2016.

20.

Participant-Informant Relationships Affect Quality of Life Ratings in Incipient and Clinical Alzheimer Disease.

Lin A, Brook J, Grill JD, Teng E.

Am J Geriatr Psychiatry. 2017 Mar;25(3):297-307. doi: 10.1016/j.jagp.2016.10.007. Epub 2016 Oct 13.

21.

Willingness to Be a Brain Donor: A Survey of Research Volunteers From 4 Racial/Ethnic Groups.

Boise L, Hinton L, Rosen HJ, Ruhl MC, Dodge H, Mattek N, Albert M, Denny A, Grill JD, Hughes T, Lingler JH, Morhardt D, Parfitt F, Peterson-Hazan S, Pop V, Rose T, Shah RC.

Alzheimer Dis Assoc Disord. 2017 Apr-Jun;31(2):135-140. doi: 10.1097/WAD.0000000000000174.

22.

Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials.

Chang TS, Teng E, Elashoff D, Grill JD; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2017 Jan-Mar;31(1):19-26. doi: 10.1097/WAD.0000000000000150.

23.

Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.

Grill JD, Zhou Y, Elashoff D, Karlawish J.

Neurobiol Aging. 2016 Mar;39:147-53. doi: 10.1016/j.neurobiolaging.2015.11.007. Epub 2015 Nov 22.

24.

Consider the Source: The Implications of Informant Type on Outcome Assessments.

Grill JD, Karlawish J.

Alzheimer Dis Assoc Disord. 2015 Oct-Dec;29(4):364. doi: 10.1097/WAD.0000000000000109. No abstract available.

25.

Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.

Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM.

JAMA Neurol. 2015 Nov;72(11):1324-33. doi: 10.1001/jamaneurol.2015.0607.

26.

A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease.

Grill JD, Bateman RJ, Buckles V, Oliver A, Morris JC, Masters CL, Klunk WE, Ringman JM; Dominantly Inherited Alzheimer’s Network.

Alzheimers Res Ther. 2015 Jul 22;7(1):50. doi: 10.1186/s13195-015-0135-0. eCollection 2015.

27.

Alzheimer's disease progression by geographical region in a clinical trial setting.

Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J.

Alzheimers Res Ther. 2015 Jun 25;7(1):43. doi: 10.1186/s13195-015-0127-0. eCollection 2015.

28.

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials.

Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL.

Alzheimers Res Ther. 2015 Jun 25;7(1):39. doi: 10.1186/s13195-015-0122-5. eCollection 2015.

29.

Does Alzheimer Disease Pathologic Change Underlie Subjective Cognitive Complaints?

Grill JD, Vinters HV, Monsell SE.

Alzheimer Dis Assoc Disord. 2015 Oct-Dec;29(4):350-2. doi: 10.1097/WAD.0000000000000092. No abstract available.

30.

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.

Harkins K, Sankar P, Sperling R, Grill JD, Green RC, Johnson KA, Healy M, Karlawish J.

Alzheimers Res Ther. 2015 May 12;7(1):26. doi: 10.1186/s13195-015-0112-7. eCollection 2015.

31.

Frequency and impact of informant replacement in Alzheimer disease research.

Grill JD, Zhou Y, Karlawish J, Elashoff D.

Alzheimer Dis Assoc Disord. 2015 Jul-Sep;29(3):242-8. doi: 10.1097/WAD.0000000000000078.

32.

Longitudinal declines in instrumental activities of daily living in stable and progressive mild cognitive impairment.

Hsiao JJ, Lu PH, Grill JD, Teng E.

Dement Geriatr Cogn Disord. 2015;39(1-2):12-24. doi: 10.1159/000365587. Epub 2014 Oct 3.

33.

Why are spousal caregivers more prevalent than nonspousal caregivers as study partners in AD dementia clinical trials?

Cary MS, Rubright JD, Grill JD, Karlawish J.

Alzheimer Dis Assoc Disord. 2015 Jan-Mar;29(1):70-4. doi: 10.1097/WAD.0000000000000047.

34.

Facilitating Alzheimer disease research recruitment.

Grill JD, Galvin JE.

Alzheimer Dis Assoc Disord. 2014 Jan-Mar;28(1):1-8. doi: 10.1097/WAD.0000000000000016. Review.

35.

Multilocus genetic profiling to empower drug trials and predict brain atrophy.

Kohannim O, Hua X, Rajagopalan P, Hibar DP, Jahanshad N, Grill JD, Apostolova LG, Toga AW, Jack CR Jr, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2013 Jun 13;2:827-35. doi: 10.1016/j.nicl.2013.05.007. eCollection 2013.

36.

Choosing Alzheimer's disease prevention clinical trial populations.

Grill JD, Monsell SE.

Neurobiol Aging. 2014 Mar;35(3):466-71. doi: 10.1016/j.neurobiolaging.2013.09.001. Epub 2013 Oct 9.

37.

Does study partner type impact the rate of Alzheimer's disease progression?

Grill JD, Zhou Y, Karlawish J, Elashoff D.

J Alzheimers Dis. 2014;38(3):507-14. doi: 10.3233/JAD-131052.

38.

The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease.

Hooper M, Grill JD, Rodriguez-Agudelo Y, Medina LD, Fox M, Alvarez-Retuerto AI, Wharton D, Brook J, Ringman JM.

Contemp Clin Trials. 2013 Sep;36(1):256-62. doi: 10.1016/j.cct.2013.07.006. Epub 2013 Jul 19.

39.

Should we disclose amyloid imaging results to cognitively normal individuals?

Grill JD, Johnson DK, Burns JM.

Neurodegener Dis Manag. 2013 Feb;3(1):43-51.

40.

Effect of study partner on the conduct of Alzheimer disease clinical trials.

Grill JD, Raman R, Ernstrom K, Aisen P, Karlawish J.

Neurology. 2013 Jan 15;80(3):282-8. doi: 10.1212/WNL.0b013e31827debfe. Epub 2012 Dec 19.

41.

Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment.

Grill JD, Karlawish J, Elashoff D, Vickrey BG.

Alzheimers Dement. 2013 May;9(3):356-359.e1. doi: 10.1016/j.jalz.2012.03.001. Epub 2012 Nov 8.

42.

Are patients whose study partners are spouses more likely to be eligible for Alzheimer's disease clinical trials?

Grill JD, Monsell S, Karlawish J.

Dement Geriatr Cogn Disord. 2012;33(5):334-40. doi: 10.1159/000339361. Epub 2012 Jul 2.

43.

Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.

Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, Chow N, Kohannim O, Cummings JL, Thompson PM, Elashoff D; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2013 Jan;34(1):62-72. doi: 10.1016/j.neurobiolaging.2012.03.006. Epub 2012 Apr 13.

44.

Should persons with autosomal dominant AD be included in clinical trials?

Grill JD, Ringman JM.

Alzheimers Res Ther. 2011 May 23;3(3):18. doi: 10.1186/alzrt80. No abstract available.

45.

Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials.

Grill JD, Karlawish J.

Alzheimers Res Ther. 2010 Dec 21;2(6):34. doi: 10.1186/alzrt58.

46.

Current therapeutic targets for the treatment of Alzheimer's disease.

Grill JD, Cummings JL.

Expert Rev Neurother. 2010 May;10(5):711-28. doi: 10.1586/ern.10.29. Review.

47.

Recognizing involuntary emotional expression disorder.

Robinson-Smith G, Grill JD.

J Neurosci Nurs. 2007 Aug;39(4):202-7.

PMID:
17847666
48.

Dendritic stability in a model of adult-onset IGF-I deficiency.

Grill JD, Sonntag WE, Riddle DR.

Growth Horm IGF Res. 2005 Oct;15(5):337-48.

PMID:
16143551
49.

Age-related and laminar-specific dendritic changes in the medial frontal cortex of the rat.

Grill JD, Riddle DR.

Brain Res. 2002 May 24;937(1-2):8-21.

PMID:
12020857
50.

Transient analgesia evoked by noxious stimulus offset.

Grill JD, Coghill RC.

J Neurophysiol. 2002 Apr;87(4):2205-8.

Supplemental Content

Loading ...
Support Center